SAFS is a relatively new disease classification; therefore, there is limited information on its clinical features. Studies are ongoing, and diagnosis is primarily made by excluding other conditions.
The criteria for diagnosis include the following:
- The presence of severe asthma that is poorly controlled with conventional treatment
- Fungal sensitisation – identified by a blood or skin prick test
- The absence of allergic bronchopulmonary aspergillosis
Similar to allergic bronchopulmonary aspergillosis (ABPA), SAFS is caused by inadequate airway clearance of inhaled fungus.
- Long-term steroids
- Biologics such as omalizumab (an anti-IgE monoclonal antibody)